NCT02669758 - A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia | Biotech Hunter

Enrollment

281

Participants

Timeline

Start Date

January 20, 2016

Primary Completion Date

June 29, 2018

Study Completion Date

June 29, 2018

Conditions

Schizophrenia

Interventions

DRUG

ALKS 3831

Tablets were administered for daily dosing

Trial Locations (31)

33161

Alkermes Investigational Site, Miami

45417

Alkermes Investigational Site, Dayton

60640

Alkermes Investigational Site, Chicago

63141

Alkermes Investigational Site, St Louis

72211

Alkermes Investigational Site, Little Rock

72764

Alkermes Investigational Site, Springdale

75243

Alkermes Investigational Site, Dallas

89102

Alkermes Investigational Site, Las Vegas

90230

Alkermes Investigational Site, Culver City

91945

Alkermes Investigational Site, Lemon Grove

92103

Alkermes Investigational Site, San Diego

92845

Alkermes Investigational Site, Garden Grove

92868

Alkermes Investigational Site, Orange

08053

Alkermes Investigational Site, Marlton

Unknown

Alkermes Investigational Site, Burgas

Alkermes Investigational Site, Kazanlak

Alkermes Investigational Site, Lovech

Alkermes Investigational Site, Novi Iskar

Alkermes Investigational Site, Plovdiv

Alkermes Investigational Site, Sofia

Alkermes Investigational Site, Tserova Koria

Alkermes Investigational Site, Veliko Tarnovo

Alkermes Investigational Site, Vratsa

Alkermes Investigational Site, Belgrade

Alkermes Investigational Site, Kragujevac

Alkermes Investigational Site, Novi Kneževac

Alkermes Investigational Site, Kharkiv

Alkermes Investigational Site, Kiev

Alkermes Investigational Site, Lviv

Alkermes Investigational Site, Stepanovka

Alkermes Investigational Site, Vinnytsia